These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 26228654)

  • 21. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study.
    McKimmie RL; Daniel KR; Carr JJ; Bowden DW; Freedman BI; Register TC; Hsu FC; Lohman KK; Weinberg RB; Wagenknecht LE
    Am J Gastroenterol; 2008 Dec; 103(12):3029-35. PubMed ID: 18853970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?
    Gambino R; Cassader M; Pagano G; Durazzo M; Musso G
    Hepatology; 2007 May; 45(5):1097-107. PubMed ID: 17464986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis.
    Vallin M; Guillaud O; Boillot O; Hervieu V; Scoazec JY; Dumortier J
    Liver Transpl; 2014 Sep; 20(9):1064-71. PubMed ID: 24961607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating very-low-density lipoprotein characteristics resulting from fatty liver in an insulin resistance rat model.
    Zago V; Lucero D; Macri EV; Cacciagiú L; Gamba CA; Miksztowicz V; Berg G; Wikinski R; Friedman S; Schreier L
    Ann Nutr Metab; 2010; 56(3):198-206. PubMed ID: 20203480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive Association Between Small Dense Low-Density Lipoprotein Cholesterol Concentration and Biomarkers of Inflammation, Thrombosis, and Prediabetes in Non-Diabetic Adults.
    Hsu SH; Jang MH; Torng PL; Su TC
    J Atheroscler Thromb; 2019 Jul; 26(7):624-635. PubMed ID: 30587667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between triglyceride-glucose index and low-density lipoprotein particle size in korean obese adults.
    Kim S; Lee JW; Lee Y; Song Y; Linton JA
    Lipids Health Dis; 2023 Jul; 22(1):94. PubMed ID: 37403101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.
    Sonmez A; Nikolic D; Dogru T; Ercin CN; Genc H; Cesur M; Tapan S; Karslioğlu Y; Montalto G; Banach M; Toth PP; Bagci S; Rizzo M
    J Clin Lipidol; 2015; 9(4):576-82. PubMed ID: 26228676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus.
    Brandman D; Pingitore A; Lai JC; Roberts JP; Ferrell L; Bass NM; Terrault NA
    Liver Transpl; 2011 Dec; 17(12):1380-6. PubMed ID: 21770018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study.
    Goff DC; D'Agostino RB; Haffner SM; Otvos JD
    Metabolism; 2005 Feb; 54(2):264-70. PubMed ID: 15690322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific Increase in Small Dense Low-Density Lipoprotein-Cholesterol Levels beyond Triglycerides in Patients with Diabetes: Implications for Cardiovascular Risk of MAFLD.
    Hirano T; Satoh N; Ito Y
    J Atheroscler Thromb; 2024 Jan; 31(1):36-47. PubMed ID: 37438123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
    Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
    Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure.
    Mutanen A; Heikkilä P; Lohi J; Raivio T; Jalanko H; Pakarinen MP
    J Hepatol; 2014 Jan; 60(1):183-90. PubMed ID: 24021426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
    Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
    Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of circulating lipoprotein lipase and adiponectin on the particle size of remnant lipoproteins in patients with diabetes mellitus and metabolic syndrome.
    Shirakawa T; Nakajima K; Yatsuzuka S; Shimomura Y; Kobayashi J; Machida T; Sumino H; Murakami M
    Clin Chim Acta; 2015 Feb; 440():123-32. PubMed ID: 25445417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter.
    Mak LY; Chan AC; Wong TC; Dai WC; She WH; Ma KW; Sin SL; Chu KW; Seto WK; Yuen MF; Lo CM; Fung J
    BMC Gastroenterol; 2023 Sep; 23(1):307. PubMed ID: 37700227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation.
    Miyaaki H; Miuma S; Taura N; Shibata H; Sasaki R; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
    Transplantation; 2019 Jan; 103(1):109-112. PubMed ID: 29894414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
    Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?
    Lucero D; Zago V; López GI; Graffigna M; López GH; Fainboim H; Miksztowicz V; Gómez Rosso L; Belli S; Levalle O; Berg G; Brites F; Wikinski R; Schreier L
    Clin Chim Acta; 2011 Mar; 412(7-8):587-92. PubMed ID: 21159313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.